-
-
Call more information
660-596-2224 -
The US Food and Drug Administration (FDA) has approved the extended-release (ER) single-entity opioid analgesic hydrocodone bitartrate (Hysingla ER, Purdue Pharma) with abuse-deterrent properties in line with the FDA’s 2013 draft guidance to industry, the agency announced. “Hysingla ER has properties that are expected to reduce, but not totally prevent, abuse of the drug when […]
Read MoreRandomized Study in Chinese and Caucasian Subjects Authors: Xinmin Wu et al Published in BMC Anesthesiol. 2014;14(53) Background This study compared efficacy and safety of the selective relaxant binding agent sugammadex (2 mg/kg) with neostigmine (50 μg/kg) for neuromuscular blockade (NMB) reversal in Chinese and Caucasian subjects. Methods This was a randomized, active-controlled, multicenter, safety-assessor-blinded study (NCT00825812) in […]
Read MoreArticle of our pain providers. Published in Pediatr Blood Cancer © 2014 Wiley Periodicals, Inc. Author(s): Anghelescu D, Goldberg J, Faughnan L, Wu J, Mao S, Furman W, Santana V, Navid F Treatments discussed: ch14.18, morphine BACKGROUND Addition of anti-GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 […]
Read MoreThis is for our pain clinic providers. The best predictor of a speedy recovery after a sports-related concussion is simply the initial symptom burden as measured by the Post-Concussion Symptom Scale (PCSS), a new study suggests. Other measures, including computerized neurocognitive testing, are not predictive, according to the study results. “The bottom line is that […]
Read MoreA study published in the November issue of the journal Pain found an increased risk of death associated with chronic pain without opioid treatment, as well as an even higher risk among those prescribed opioids for long-term use and a somewhat lower risk associated with short-term use. “Our study provides the first evidence that directly […]
Read More